FDA grants priority review to Tevimbra combo in HER2+ GEA: full analysis

CURRENT FULL VERSION: BeOne Medicines has won FDA Priority Review for a supplemental biologics license application seeking to expand Tevimbra, or tislelizumab, into first-line treatment of HER2-positive gastroesophageal adenocarcinoma in combination with zanidatamab-hrii and chemotherapy. The proposed indication covers adults with unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, and the accelerated review puts the application on track for an FDA decision in the third quarter of 2026. BeOne also said it plans to participate in the FDA’s Project Orbis program, which could support coordinated review with other health authorities. (nasdaq.com)

The filing builds on HERIZON-GEA-01, a global phase 3 trial jointly tied to BeOne, Jazz, and Zymeworks. The study tested whether zanidatamab, a HER2-targeted bispecific antibody, could improve on the longstanding trastuzumab-plus-chemotherapy backbone, and whether adding the PD-1 inhibitor tislelizumab could push outcomes further. That question matters because the first-line HER2-positive gastric and GEJ space has already been evolving: in March 2025, the FDA approved pembrolizumab with trastuzumab and chemotherapy for PD-L1-positive HER2-positive gastric or GEJ adenocarcinoma, raising the bar for new entrants and making survival differentiation especially important. (nasdaq.com)

At the 2026 ASCO GI Cancers Symposium, investigators reported that the tislelizumab-containing HERIZON-GEA-01 arm met the trial’s co-primary goals, showing statistically significant improvements in progression-free survival and overall survival versus trastuzumab plus chemotherapy. Across 914 previously untreated adults with metastatic or locally advanced unresectable disease, median overall survival was 26.4 months with zanidatamab, tislelizumab, and chemotherapy, compared with 19.2 months in the control arm, with a hazard ratio of 0.72. Median progression-free survival was 12.4 months in the tislelizumab-containing arm versus 8.1 months in the control arm. Reports from the meeting also described a median overall survival of 24.4 months for zanidatamab plus chemotherapy without tislelizumab, and that arm also reached a median progression-free survival of 12.4 months, though its overall survival readout was described as an interim trend rather than a statistically significant win at that analysis. Company materials said benefit was observed regardless of PD-L1 status, a potentially important point in a treatment setting where PD-L1 expression already affects use of competing immunotherapy regimens. (ascopost.com)

The regulatory activity has been moving on both components of the regimen. BeOne announced Priority Review for Tevimbra, while Jazz separately said the FDA also accepted and granted Priority Review to the supplemental application for Ziihera combinations in the same first-line HER2-positive gastroesophageal setting. That parallel movement suggests the agency is reviewing the regimen as a coordinated package, which could matter for launch timing, labeling, and uptake if both applications are cleared on similar timelines. BeOne’s stated interest in Project Orbis adds another layer, since it raises the possibility of near-parallel regulatory discussions outside the US as well. (nasdaq.com)

Reaction from oncology specialists has been notably positive. In company-cited commentary, Manish Shah of Weill Cornell said the survival outcome in the tislelizumab-containing arm surpassed two years and marked a significant advance in metastatic HER2-positive gastroesophageal adenocarcinoma. Separately, ASCO expert Rachna Shroff called the findings practice-changing and said they offer a new treatment option for patients with HER2-positive upper GI cancers. Those comments should be read with the usual caution around conference-era data and company-linked expert remarks, but they do reflect a broader sense that the regimen could reset expectations in this niche. (nasdaq.com)

Why it matters: For veterinary professionals, this is adjacent rather than direct practice news, but it still has relevance. Comparative oncology increasingly tracks advances in immuno-oncology, bispecific antibodies, and biomarker-selected treatment strategies in people because those platforms often influence research priorities, translational collaborations, and investor appetite across animal health and oncology innovation. The bigger signal here is that regulators appear receptive to complex, targeted combination regimens when survival data are strong. The reported activity regardless of PD-L1 status also hints at a regimen that may reach beyond narrower biomarker-defined slices of the market, which is relevant when people in translational and comparative oncology think about how broadly a platform might apply. (nasdaq.com)

What to watch: The next milestones are the FDA decision expected in Q3 2026, fuller safety and subgroup scrutiny as the data mature, and eventual peer-reviewed publication of HERIZON-GEA-01. It will also be worth watching whether the PD-L1-independent benefit holds up in fuller reporting, whether Project Orbis leads to additional regulatory filings or decisions abroad, and whether the regimen’s benefit appears broad enough to compete across biomarker-defined subgroups in a market where pembrolizumab-based first-line therapy is already established for PD-L1-positive HER2-positive gastric and GEJ disease. (nasdaq.com)